Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

por Tabernero, J., Velez, L., Trevino, T.L., Grothey, A., Yaeger, R., Van Cutsem, E., Wasan, H., Desai, J., Ciardiello, F., Yoshino, T., Gollerkeri, A., Maharry, K., Christy-Bittel, J., Kopetz, S.
Publicado 2021